News stories about Tonix Pharmaceuticals (NASDAQ:TNXP) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Tonix Pharmaceuticals earned a news impact score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.2300136978113 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Tonix Pharmaceuticals (TNXP) traded up $0.36 during mid-day trading on Friday, hitting $4.46. 85,356 shares of the stock traded hands, compared to its average volume of 62,646. Tonix Pharmaceuticals has a fifty-two week low of $2.85 and a fifty-two week high of $9.40.

Several research firms have issued reports on TNXP. Roth Capital upgraded shares of Tonix Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research note on Friday, August 18th. They noted that the move was a valuation call. Dawson James restated a “buy” rating and issued a $9.00 target price on shares of Tonix Pharmaceuticals in a research note on Wednesday, August 23rd. ValuEngine downgraded shares of Tonix Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, October 2nd. Finally, Drexel Hamilton began coverage on shares of Tonix Pharmaceuticals in a research note on Tuesday, August 22nd. They issued a “buy” rating for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $8.33.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

Insider Buying and Selling by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.